A CRMO diagnosis (Chronic Recurrent Multifocal Osteomyelitis) can bring a strange mix of relief and overwhelm. After months or sometimes years of unexplained bone pain, limping, and inconclusive tests, finally having a name for what's happening to your child is a milestone. But it often arrives with a flood of unfamiliar terms and no clear map of what comes next.
This guide is written for parents and caregivers navigating those early days. We've organized what we've learned from clinical resources, medical advisors, and the CRMO family community into five areas that matter most. Take it at your own pace.
A note on adults: CRMO/CNO also affects adults in significant numbers, and adult patients face distinct challenges including limited specialist access and less research attention. This guide focuses on pediatric diagnosis and care; a companion adult guide is in development.
CRMO is a rare, autoinflammatory bone condition, though it appears to be more common than previously thought. Recent research suggests CRMO may be nearly as common as bacterial bone infections, with many children remaining undiagnosed or misdiagnosed for years. Understanding what CRMO is, and what it isn't, is the foundation for everything that follows.
CRMO stands for Chronic Recurrent Multifocal Osteomyelitis. Despite the name, it is not a bone infection. It is a sterile autoinflammatory bone disease in which abnormal innate immune activity causes bone inflammation. That inflammation can also promote osteoclast-driven bone breakdown, which helps explain bone lesions and, in severe cases, complications such as fracture or vertebral collapse.
Lesions typically affect the long bones, clavicle, spine, and pelvis, in a pattern of flares and remissions. CNO (Chronic Non-Bacterial Osteomyelitis) is now the preferred term among many specialists. The broader name was chosen because not all cases are multifocal or recurrent. CNO captures the full spectrum. CRMO and CNO are increasingly used interchangeably in clinical practice, and CNO is also now the term used for adult-onset disease. SAPHO syndrome, which shares some features, is increasingly understood as a distinct condition rather than simply the adult form of CRMO.
On the diagnostic delay: The median time to diagnosis is 15 months. Many families report a 2+ year odyssey where children are told they have growing pains, a sports injury, or even a bacterial bone infection. This delay is common and not a failure on your part.
There is no single definitive test. Diagnosis is made by an experienced pediatric rheumatologist based on clinical findings, imaging, and exclusion of other causes. Key tools:
Contact your rheumatologist or go to the emergency department without waiting if your child develops any of the following:
When in doubt, call your rheumatology team before waiting for the next scheduled appointment.
Yes, especially if CRMO was diagnosed outside a major pediatric academic center. Expertise is concentrated at a small number of centers nationally. A second opinion from a rheumatologist with CRMO or CNO experience can confirm the diagnosis, identify subclinical lesions, and ensure a comprehensive treatment plan.
CRMO has a complex genetic background still under active study. Variants involving the IL-1 pathway have been associated with the condition, but it's not inherited in a simple pattern. Siblings have a somewhat elevated risk, but absolute risk remains low. Discuss with your rheumatologist if siblings develop unexplained bone pain.
A small subset of cases are caused by identified single-gene variants. These tend to present with distinct clinical features and may respond to specific treatments. Known associations are summarized below.
| Gene / Locus | Clinical phenotype | Notes |
|---|---|---|
| LPIN2 | Majeed syndrome: early-onset CRMO (often before age 2), congenital dyserythropoietic anemia, sometimes neutrophilic dermatosis | Inflammation is IL-1 mediated; IL-1 blockade (e.g., anakinra) is effective |
| IL1RN | Atypical DIRA (Deficiency of IL-1 Receptor Antagonist): systemic inflammation, fevers, serositis, and multifocal bone inflammation resembling CRMO on imaging | Rapid remission with anakinra; switching to canakinumab (IL-1β selective) led to a flare, suggesting full IL-1 receptor antagonism is needed |
| FBLIM1 | Non-syndromic CRMO: recurrent bone pain and sterile osteomyelitis with imaging consistent with CRMO; some family members also had psoriasis or IBD | Functional studies suggest loss-of-function dysregulates bone remodeling (ERK1/2 → RANKL) and anti-inflammatory signaling (IL-10) |
| Chromosome 18q21–22 locus | Recurrent inflammatory bone lesions with metaphyseal involvement of long bones in a family-based study (haplotype relative risk of 18) | Causative gene in this locus has not been definitively identified |
CRMO care centers on pediatric rheumatology, but your child may need involvement across multiple specialties. Learning how to navigate this system and communicate your child's history effectively is one of the highest-leverage investments you can make.
Your pediatric rheumatologist is the primary coordinator of your care team. Depending on your child's presentation, you may also need:
CRMO treatment is typically escalated based on lesion location, severity, spinal involvement, and response to first-line therapy. Approaches vary across centers.
Note on off-label use: Many CRMO biologics are FDA-approved for other conditions but not specifically for CRMO. This is standard of care in rare pediatric diseases, but it creates insurance barriers. See Section 4.
CRMO is a long-term condition. Treatment often lasts months to years, and the disease can recur after medication is stopped. Families should expect a rhythm of regular rheumatology follow-up, which typically includes:
Some children respond well to NSAIDs alone, while others need escalation to bisphosphonates or biologics. Your rheumatologist will adjust the plan based on how your child responds — this is expected, not a sign that something went wrong.
CRMO/CNO is rare enough that generating clinical evidence depends heavily on family and patient participation. The CARRA Registry is the primary North American pediatric rheumatic disease registry. Closely related is CHOIR (the CHronic nonbacterial Osteomyelitis International Registry), which was established by the CARRA CNO/CRMO workgroup and is specifically focused on CNO/CRMO patients. Ask your rheumatologist if your center participates in either. Check ClinicalTrials.gov for open studies.
Voice-based check-ins, structured symptom logs, and Visit Companion tools designed specifically for your rheumatology appointments. Free for families.
Request Beta Access →CRMO is a condition your child lives with in the classroom, on the playground, and at home, not just in the clinic. Securing appropriate school accommodations and managing day-to-day life during flares is essential to protecting both health and quality of life.
Many children with CRMO may qualify for a Section 504 Plan, depending on how symptoms affect school functioning. A 504 Plan is a formal document that requires schools to provide accommodations for students whose health condition substantially limits a major life activity — pain and mobility limitations during flares often meet this threshold, but the school must conduct an evaluation. (A 504 Plan differs from an IEP: a 504 provides accommodations within general education, while an IEP provides specialized instruction. Many children with CRMO need a 504 rather than an IEP, unless they also need specialized instruction for another reason.) Accommodations to consider requesting:
Know your rights: You can request a 504 evaluation at any time. Once a plan is in place, you can request written amendments to add accommodations. Schools are required to consider and respond to written requests.
CRMO is an invisible illness much of the time. Children may look completely healthy on good days. A brief written explanation of CRMO shared with the school nurse and homeroom teacher at the start of each year is valuable. A letter on clinic letterhead from your rheumatologist carries significant weight in school planning meetings.
Beyond scheduled medications, many families find physical therapy (when tailored to CRMO), heat and ice therapy, and pediatric pain psychology useful. Ask your rheumatologist for referrals if pain is significantly impacting mood, sleep, or school attendance. This is not something families should navigate alone.
CRMO treatment can be expensive, and navigating insurance for a rare, poorly understood disease is one of the most exhausting parts of the journey. Prior authorization denials and off-label prescription barriers are common. Understanding the system and your rights is essential.
NSAIDs are typically covered without issues. But pamidronate infusions, TNF inhibitors, and newer biologics routinely require prior authorization and are frequently denied on first submission. Most families win on appeal with strong documentation. An effective appeal includes:
Document every insurance call: Log the date, time, representative name, and summary of what was discussed. This documentation strengthens appeals and is essential if you escalate to an external review.
Manufacturers of biologic medications commonly prescribed for CRMO offer patient assistance programs that can significantly reduce or eliminate out-of-pocket costs. Ask your rheumatologist's care coordinator about manufacturer copay cards and patient support programs for your child's specific medication.
Even if your family income exceeds standard Medicaid limits, children with significant chronic conditions may qualify through the Katie Beckett / TEFRA waiver, which bases eligibility on the child's own income rather than family income. A social worker at your pediatric rheumatology center can help identify what's available in your state.
For children receiving pamidronate, where the infusion is administered matters for coverage. Hospital outpatient, freestanding infusion center, and in-office settings are billed differently. Call your insurer before the first infusion to confirm site-of-care coverage and cost-sharing.
Timestamped, structured flare and medication records from CRMO Care make prior authorization letters and insurance appeals significantly stronger. Every check-in builds your case.
Start Tracking →CRMO affects a small but growing number of children each year, but that doesn't mean you navigate it alone. The CRMO family community, while small, is remarkably tight-knit, well-informed, and active. Connecting with other families early is one of the highest-value things you can do.
Other CRMO parents have navigated what you're facing right now: the diagnostic uncertainty, the insurance fights, the school accommodation battles, the fear before each MRI. Their collective knowledge is practical, specific, and impossible to find anywhere else.
Facebook hosts the largest gatherings of CRMO/CNO patients and families. The most established group is CRMO: Chronic Recurrent Multifocal Osteomyelitis. There is also a separate active group specifically for adult CNO patients. A word of caution: there are many CRMO-related groups online, and not all provide accurate information or a supportive environment. Seek out well-moderated communities and, when in doubt, verify medical information with your care team.
CARRA brings together the researchers and clinicians driving CRMO science forward. Their annual scientific meeting is a major gathering point for the community. Ask your rheumatologist about family advisory panel opportunities.
CRMO Care was built by a CRMO family, specifically to fill gaps that other tools couldn't. Every family that tracks consistently helps build the evidence base that will improve care for CRMO children diagnosed in the future. Join 100+ families already enrolled →
CRMO Care is free for families. Your participation also contributes to the research that will improve outcomes for every CRMO child diagnosed in the future.
Join 100+ CRMO Families →Many children with CRMO achieve sustained remission and return to full activity. Even for children with more persistent disease, treatment options today are meaningfully better than a decade ago, and the research pipeline continues to grow.
Progress comes less from having all the answers on day one and more from building the right team, staying organized, connecting with your community, and advocating confidently for your child.
CRMO Care is a pediatric symptom tracking platform built specifically for families managing CRMO. Founded by a CRMO parent with direct experience navigating diagnosis, treatment decisions, insurance barriers, and school accommodations. Our medical advisors include pediatric rheumatologists with specialized CRMO expertise and researchers affiliated with CARRA.
This guide is for informational purposes only and does not constitute medical advice. Always consult a qualified pediatric rheumatologist or licensed healthcare provider for diagnosis and treatment decisions specific to your child.